Evidence map›Paper›PMID 39872888›Full record

ArticleLife medicine2023

Efficient repair of human genetic defect by CRISPR/Cas9-mediated interlocus gene conversion.

Fei Yang, Yiyun Wang, Qiudao Wang, Jingtao Pang, Guolong Liu, Yang Yang, Shenguang Qin, Ying Zhang, Yongrong Lai, Bin Fu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fei YangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
Yiyun WangGansu Institute for Drug Control, Lanzhou 730070, China.
Qiudao WangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
Jingtao PangBRL Medicine Inc., Shanghai 201108, China.
Guolong LiuShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
Yang YangDepartment of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530000, China.
Shenguang QinBRL Medicine Inc., Shanghai 201108, China.
Ying ZhangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
Yongrong LaiDepartment of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530000, China.
Bin FuDepartment of Hematology, Xiangya Hospital of Central South University, Changsha 410008, China.
Yating ZhuDepartment of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Mengyao WangDepartment of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Ryo KuritaDepartment of Research and Development, Central Blood Institute, Japanese Red Cross Society, Tokyo 135-8521, Japan.
Yukio NakamuraCell Engineering Division, RIKEN BioResource Center, Tsukuba 305-0074, Japan.
Dan LiangDepartment of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Yuxuan WuShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA double-strand breaks (DSBs) induced by gene-editing tools are primarily repaired through non-homologous end joining (NHEJ) or homology-directed repair (HDR) using synthetic DNA templates. However, error-prone NHEJ may result in unexpected indels at the targeted site. For most genetic disorders, precise HDR correction using exogenous homologous sequence is ideal. But, the therapeutic application of HDR might be especially challenging given the requirement for the codelivery of exogenous DNA templates with toxicity into cells, and the low efficiency of HDR could also limit its clinical application. In this study, we efficiently repair pathogenic mutations in

Indexed as

CRISPRgene conversiongene therapyhematopoietic stem cellsβ-thalassemia

Identifiers

PMID39872888
PMCPMC11749481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.